These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
918 related articles for article (PubMed ID: 23896980)
1. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Szepietowski JC; Nilganuwong S; Wozniacka A; Kuhn A; Nyberg F; van Vollenhoven RF; Bengtsson AA; Reich A; de Vries DE; van Hartingsveldt B; Robinson DW; Gordon R; Hsu B Arthritis Rheum; 2013 Oct; 65(10):2661-71. PubMed ID: 23896980 [TBL] [Abstract][Full Text] [Related]
2. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Merrill JT; Wallace DJ; Petri M; Kirou KA; Yao Y; White WI; Robbie G; Levin R; Berney SM; Chindalore V; Olsen N; Richman L; Le C; Jallal B; White B; Ann Rheum Dis; 2011 Nov; 70(11):1905-13. PubMed ID: 21798883 [TBL] [Abstract][Full Text] [Related]
3. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Kalunian KC; Davis JC; Merrill JT; Totoritis MC; Wofsy D; Arthritis Rheum; 2002 Dec; 46(12):3251-8. PubMed ID: 12483729 [TBL] [Abstract][Full Text] [Related]
4. Belimumab: review of use in systemic lupus erythematosus. Boyce EG; Fusco BE Clin Ther; 2012 May; 34(5):1006-22. PubMed ID: 22464040 [TBL] [Abstract][Full Text] [Related]
6. Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Smolen JS; Weinblatt ME; Sheng S; Zhuang Y; Hsu B Ann Rheum Dis; 2014 Sep; 73(9):1616-25. PubMed ID: 24699939 [TBL] [Abstract][Full Text] [Related]
7. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Merrill JT; Ginzler EM; Wallace DJ; McKay JD; Lisse JR; Aranow C; Wellborne FR; Burnette M; Condemi J; Zhong ZJ; Pineda L; Klein J; Freimuth WW; Arthritis Rheum; 2012 Oct; 64(10):3364-73. PubMed ID: 22674457 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Choy EH; Isenberg DA; Garrood T; Farrow S; Ioannou Y; Bird H; Cheung N; Williams B; Hazleman B; Price R; Yoshizaki K; Nishimoto N; Kishimoto T; Panayi GS Arthritis Rheum; 2002 Dec; 46(12):3143-50. PubMed ID: 12483717 [TBL] [Abstract][Full Text] [Related]
9. Effect of raloxifene on disease activity and vascular biomarkers in patients with systemic lupus erythematosus: subgroup analysis of a double-blind randomized controlled trial. Mok CC; Ying SK; Ma KM; Wong CK Lupus; 2013 Dec; 22(14):1470-8. PubMed ID: 24113197 [TBL] [Abstract][Full Text] [Related]
10. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Furie R; Petri M; Zamani O; Cervera R; Wallace DJ; Tegzová D; Sanchez-Guerrero J; Schwarting A; Merrill JT; Chatham WW; Stohl W; Ginzler EM; Hough DR; Zhong ZJ; Freimuth W; van Vollenhoven RF; Arthritis Rheum; 2011 Dec; 63(12):3918-30. PubMed ID: 22127708 [TBL] [Abstract][Full Text] [Related]
11. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Wallace DJ; Stohl W; Furie RA; Lisse JR; McKay JD; Merrill JT; Petri MA; Ginzler EM; Chatham WW; McCune WJ; Fernandez V; Chevrier MR; Zhong ZJ; Freimuth WW Arthritis Rheum; 2009 Sep; 61(9):1168-78. PubMed ID: 19714604 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study. Stohl W; Schwarting A; Okada M; Scheinberg M; Doria A; Hammer AE; Kleoudis C; Groark J; Bass D; Fox NL; Roth D; Gordon D Arthritis Rheumatol; 2017 May; 69(5):1016-1027. PubMed ID: 28118533 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Xu Z; Bouman-Thio E; Comisar C; Frederick B; Van Hartingsveldt B; Marini JC; Davis HM; Zhou H Br J Clin Pharmacol; 2011 Aug; 72(2):270-81. PubMed ID: 21392075 [TBL] [Abstract][Full Text] [Related]
14. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. Ginzler EM; Wallace DJ; Merrill JT; Furie RA; Stohl W; Chatham WW; Weinstein A; McKay JD; McCune WJ; Zhong ZJ; Freimuth WW; Petri MA; J Rheumatol; 2014 Feb; 41(2):300-9. PubMed ID: 24187095 [TBL] [Abstract][Full Text] [Related]
15. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1088 patients in Sweden. Grönhagen CM; Fored CM; Granath F; Nyberg F Br J Dermatol; 2011 Jun; 164(6):1335-41. PubMed ID: 21574972 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus. Bengtsson AA; Sturfelt G; Lood C; Rönnblom L; van Vollenhoven RF; Axelsson B; Sparre B; Tuvesson H; Ohman MW; Leanderson T Arthritis Rheum; 2012 May; 64(5):1579-88. PubMed ID: 22131101 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. van Vollenhoven RF; Hahn BH; Tsokos GC; Wagner CL; Lipsky P; Touma Z; Werth VP; Gordon RM; Zhou B; Hsu B; Chevrier M; Triebel M; Jordan JL; Rose S Lancet; 2018 Oct; 392(10155):1330-1339. PubMed ID: 30249507 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Wallace DJ; Gordon C; Strand V; Hobbs K; Petri M; Kalunian K; Houssiau F; Tak PP; Isenberg DA; Kelley L; Kilgallen B; Barry AN; Wegener WA; Goldenberg DM Rheumatology (Oxford); 2013 Jul; 52(7):1313-22. PubMed ID: 23542611 [TBL] [Abstract][Full Text] [Related]
19. Anti-nucleosome and anti-chromatin antibodies are present in active systemic lupus erythematosus but not in the cutaneous form of the disease. Souza A; da Silva LM; Oliveira FR; Roselino AM; Louzada-Junior P Lupus; 2009 Mar; 18(3):223-9. PubMed ID: 19213860 [TBL] [Abstract][Full Text] [Related]
20. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Chang DM; Lan JL; Lin HY; Luo SF Arthritis Rheum; 2002 Nov; 46(11):2924-7. PubMed ID: 12428233 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]